VANCOUVER, Oct. 10, 2013 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company", TSX.V: WBI) announces today the results of its substantial issuer
bid, pursuant to which the Company offered to purchase for cancellation
up to 23,529,411 of its issued and outstanding common shares ("Shares") at a purchase price of $0.85 per Share for an aggregate purchase
price of up to $20 million (the "Offer"). The offer expired at 5:00 p.m. (Toronto time) on October 9, 2013.
Based on the final report provided by the depositary for the Offer, a
total of 26,356,197 Shares with an aggregate purchase price exceeding $20 million have been
deposited and not withdrawn and, as a result, 23,529,411 Shares with an
aggregate purchase price of $20 million will be purchased for
cancellation from all shareholders who have tendered their Shares on a
pro-rata basis. The Shares being purchased for cancellation represent
approximately 28.4% of the issued and outstanding Shares of the Company
outstanding as of October 9, 2013 and, following the purchase and
cancellation of these Shares, approximately 59,462,658 Shares will remain outstanding.
The Company confirms that, as of the date hereof, the amount of paid-up
capital to be allocated to each Share is $0.198 and the amount of the
deemed dividend per Share is $0.652.
Take-up and payment for all Shares validly deposited under the Offer and
accepted for purchase by the Company will be made as soon as
practicable by The Laurel Hill Advisory Group Company, which was
retained by the Company to act as depositary in connection with the
Offer. If shareholders have any questions related to the Offer, they
can contact Laurel Hill by telephone at 1-877-452-7184 or by email at email@example.com.
The full details of the Offer are described in the Company's offer to
purchase and issuer bid circular dated August 30, 2013 which is filed
on SEDAR along with the related letter of transmittal.
This press release is for information purposes only and is not an offer
to buy or the solicitation of an offer to sell any Shares. This
document does not constitute an offer or a solicitation to any person
in any jurisdiction in which such offer or solicitation is unlawful.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and
cancers. For a more complete business and financial profile of the
Company, interested parties are encouraged to visit the Company's
Forward looking statements:
Certain statements and other information included in this press release
constitute "forward-looking information" within the meaning of
applicable Canadian securities legislation. All statements in this
press release, other than those relating to historical information or
current conditions, are forward-looking statements, including
information with respect to the Offer. Forward-looking statements and
forward-looking information are based on information available at the
time they are made, underlying estimates and assumptions made by
management and management's good faith belief with respect to future
events, performance and results, and are subject to inherent risks and
uncertainties surrounding future expectations generally. Such risks and
uncertainties include, but are not limited to the Company's ability to
successfully implement its business strategy and activities, changes to
the regulatory and economic environment in which the Company operates
now and in the future, including changes in accounting policies or
pronouncements introduced by regulatory authorities, changes in the
Company's tax liabilities, either through changes in tax laws or future
assessments, and any material disruption to the Company's operations,
among other things. Actual results and developments are likely to
differ, and may differ materially, from those expressed or implied by
the forward-looking information contained in this press release. Such
statements are based on a number of assumptions which may prove to be
incorrect, including, but not limited to, assumptions about general
business and economic conditions; interest rates and foreign exchange
rates; tax benefits and tax rates. Welichem disclaims any intention or
obligation to update or revise any forward-looking statements in this
press release as a result of new information or future events, except
as may be required under applicable Canadian securities legislation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Welichem Biotech Inc.
For further information:
Liren Tang, President and Chief Executive Officer. Tel.: (604) 432-1703, Email: firstname.lastname@example.org